FDA Approves Updated COVID-19 Vaccines Targeting Latest LP.8.1 Variant for High-Risk and Older Adults

Highlight

• The US FDA approved updated COVID-19 vaccines from Pfizer and Moderna targeting the LP.8.1 sublineage.
• Vaccines are indicated for adults aged 65 years and older, and individuals aged 5 to 64 years with high-risk underlying conditions.
• Pfizer’s COMIRNATY and Moderna’s SPIKEVAX and mNEXSPIKE vaccines showed safety and improved immune responses in clinical and preclinical studies.
• Updated vaccines have global regulatory approvals and are ready for immediate distribution.

Study Background and Disease Burden

The ongoing COVID-19 pandemic continues to pose significant public health challenges, particularly due to the virus’s ability to evolve and evade immune responses. Variants of SARS-CoV-2 have emerged with mutations that can reduce vaccine effectiveness, especially concerning older adults and individuals with underlying health conditions that increase their risk of severe COVID-19 outcomes. These populations have a heightened vulnerability to hospitalization, complications, and mortality from COVID-19. Consequently, there is an unmet medical need for updated vaccines tailored to circulating variants to sustain protective immunity and reduce disease burden.

Study Design and Regulatory Approval Context

The US Food and Drug Administration (FDA) recently granted supplemental Biologics License Application (sBLA) approvals for updated COVID-19 vaccines by Pfizer and Moderna. These vaccines target the LP.8.1 sublineage, a recent variant reflecting the virus’s antigenic evolution.

Moderna’s SPIKEVAX was updated and approved for individuals aged six months through 64 years with at least one high-risk underlying condition and for all adults aged 65 years and older. Additionally, Moderna’s newer vaccine mNEXSPIKE received approval for individuals aged 12 through 64 years with qualifying high-risk conditions and adults 65 years or older.

Pfizer’s updated COMIRNATY vaccine was approved for all adults 65 and older and individuals aged 5 to 64 with high-risk conditions. These decisions were based on clinical trial data demonstrating safety and efficacy, including in pediatric groups aged 5-11 years, and supported by preclinical immunogenicity data against multiple circulating subvariants.

Key Findings

Both manufacturers’ vaccines are designed to enhance immunity against the LP.8.1 sublineage, in alignment with FDA guidance. The approval of Pfizer’s vaccine was strongly supported by data demonstrating robust safety profiles and improved neutralizing antibody responses across age groups, including children. The clinical trials included endpoints such as prevention of symptomatic COVID-19 infection and assessment of adverse events, which met FDA criteria for efficacy and safety.

Moderna’s updated vaccines have similarly shown strong immunogenicity and safety profiles. Importantly, the mNEXSPIKE vaccine provides an expanded age indication and targets high-risk populations effectively. These formulations incorporate updated mRNA sequences to broaden immune coverage against antigenically drifted variants.

The updated vaccines represent a strategic evolution in the COVID-19 vaccination program aiming to maintain protection in the face of viral evolution. Both companies report these vaccines are ready for immediate shipment and should be accessible to clinicians within days, facilitating rapid immunization campaigns focused on the most vulnerable populations.

Expert Commentary

Experts recognize the FDA’s approval of these updated vaccines as a critical step toward adapting immunization strategies to SARS-CoV-2’s dynamic landscape. Incorporating variant-specific sequences enhances the vaccine’s biological plausibility for improved protection. Notably, extending eligibility to younger patients with high-risk conditions reflects evolving epidemiological data pointing to persistent risk despite prior immunization efforts.

Limitations include that long-term effectiveness against emerging variants remains under surveillance, given the rapid pace of viral mutation. Also, broader population data beyond high-risk and older adults are needed to understand the vaccine utility spectrum in the general population.

Conclusion

The FDA’s approval of updated Pfizer and Moderna COVID-19 vaccines targeting the LP.8.1 sublineage represents a key advancement in protecting high-risk groups and older adults against current SARS-CoV-2 variants. These approvals expand age and risk group indications, supported by rigorous clinical and immunological data. Immediate availability will enable timely vaccination efforts to mitigate severe outcomes. Continued research and surveillance remain essential to address ongoing viral evolution and optimize vaccine deployment strategies.

References

• FDA News Release. FDA Approves Updated COVID-19 Vaccines for Specific Populations. 2024.
• Moderna, Inc. Press Release on FDA Approval of Updated SPIKEVAX and mNEXSPIKE Vaccines, 2024.
• Pfizer Inc. Press Release on FDA Approval of Updated COMIRNATY Vaccine, 2024.
• CDC COVID-19 Vaccination Guidance for High-Risk Individuals, 2024.
• World Health Organization. COVID-19 Variant Tracking and Vaccine Recommendations. 2024.